About 20% children with allergic purpura develop nephritis syndrome or nephrotic syndrome, 1% to 7% to kidney failure or end-stage renal disease. Children with serious damage to health, significantly reduced quality of life and caused heavy economic burden to the family . As the pathogenesis of HSPN is complex, it is difficult to formulate an exact individualized treatment plan.
Children of Purpura nephritis with moderate protenuria(24 hours urinary protein quantitative 0.5 \~ 1.0 1.73 g/m2 and 24 hours urinary protein amount of not more than 1.0 g) in this study was choosed as participatant, plan randomly into the group of 10 cases, treated with huaiqihuang particles and valsartan for 24 weeks to analyze the curative effect and clinical value of single drug therapy for children with purpura nephritis in reducing proteinuria, protecting renal function and promoting rehabilitation.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
10
Huaiqihuang granules are composed of Huaier fungus, Fructus lycii and Huangjing. Studies have shown that huaiqihuang treatment can reduce cytokines in children with purpura nephritis interleukins IL - 4, IL - 10 and the tumor necrosis factor alpha (TNF alpha) expression level, prompt huaiqihuang granule treating children allergic purpura nephritis can significantly improve the clinical curative effect, improve the level of cytokines and the patient's immune function, and does not increase the incidence of adverse reactions.
Valsartan granules 80mg/1.73m2 based qd 24 weeks
The Children Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Children's Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
change of urinary protein
24-hour urinary protein quantitative, urinary microprotein
Time frame: before Clinical trials; 1 month, 2 months, 3 months, 6 months after randomization
Change in renal function of the patients
blood chemistry
Time frame: before Clinical trials; 1 month, 2 months, 3 months, 6 months after randomization
change of lymphocyte subsets
including Th1 cells, Th2 cells, Th17 cells, cytokines (IL-16, IL-10, IL-17, etc.)
Time frame: before Clinical trials; 1 month, 2 months, 3 months, 6 months after randomization
change of immunoglobulin + complement
immunoglobulin + complement
Time frame: before Clinical trials; 1 month, 2 months, 3 months, 6 months after randomization
change of urine red blood cells
red blood cells routine urine
Time frame: before Clinical trials; 1 month, 2 months, 3 months, 6 months after randomization
Change of blood pressure
blood pressure
Time frame: before Clinical trials; 1 month, 2 months, 3 months, 6 months after randomization
change of BMI(Body Mass Index)
calculated by dividing weight in kilograms by height in meters squared( kg/m\^2)
Time frame: before Clinical trials; 1 month, 2 months, 3 months, 6 months after randomization
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.